BioSpace News Archive

Expedeon AG (Frankfurt: EXNN; ISIN: DE000A2YN801; Prime Standard) today announced that the Company’s Extraordinary General Meeting (EGM) held in Heidelberg today has approved all management proposals by a large majority without objection.

ONCOLOGY PHARMA, INC. is pleased to announce that it has received a letter of intent dated December 20th to facilitate a financing of US$ 38.4 Million from SCP Investment Partners, Ltd, UK.

Luye Pharma Group has announced submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for LY03005, a new chemical drug for the treatment of major depressive disorder.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc. (CEO: James Knighton, “Xyphos”) today announced that Astellas has acquired Xyphos.

Today, Lieutenant Governor Karyn Polito joined Massachusetts Life Sciences Center (MLSC) President and CEO Travis McCready, leaders from the Massachusetts Biomedical Initiatives (MBI), and state and local officials at the site of MBI’s expansion to celebrate construction progress of the redeveloped facility, which will double the operational capacity for the life sciences incubator.

Spring Bank Pharmaceuticals, Inc. announced that the company has stopped dosing and enrolling patients in its Phase 2b CATALYST trials, which are examining the use of inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus.

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today reported that its pre-specified primary endpoint in its Phase 2 clinical trial evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations was not met in Cohort 1.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the“Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced it has received Tens of Thousands of Dollars worth of Purchase Orders from multiple International / Kosher Distributors

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that the company’s founder, Lewis T. “Rusty” Williams, M.D., Ph.D., has resigned as a member of the Five Prime Board of Directors to focus on his role as Chief Executive Officer of Walking Fish Therapeutics